ReCode Therapeutics Reports the Preclinical Data of RCT2100 for Cystic Fibrosis
Shots:
- ReCode highlighted the non-clinical data of mRNA-based RCT2100 for the treatment of cystic fibrosis at NACFC 2024
- Results showed that RCT2100 restored up to 135% CFTR function in human bronchial epithelial (HBE) cells form CF patients compared to elexacaftor/tezacaftor/ivacaftor. In vivo study showed improved mucociliary clearance (MCC) post-treatment in G551D CF ferret model, indicating its potential for CF patients ineligible for current therapies
- RCT2100 is an inhaled therapy developed using SORT LNP platform for CF patients, unresponsive to current therapies and with class I CFTR gene mutation. It delivers CFTR mRNA to make functional CFTR protein in target cells
Ref: ReCode Therapeutics | Image: ReCode Therapeutics
Related News:- Vertex’s Kaftrio+Ivacafor Receives EC’s Approval for the Treatment of Children aged 2 to 5yrs. with Cystic Fibrosis (CF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
